TIANMU Pharmaceutical Industry: The concept of red eye disease "leading" repeated violations

"Superbugs" has not been completely extinct, the tick storm has just subsided, red eye disease and attack all over.　　The hot money in the slightest let this hype opportunity, the concept of red eye disease swept the capital market.　　Red eye disease is "acute infectious conjunctivitis" commonly known as, Guangdong, Jiangsu, Henan, Hunan, Shandong and other recent outbreaks of red eye diseases, for the treatment of eye drops demand for a large increase. The production of eye drops, eye ointment, such as stocks, such as Tianmu Pharmaceutical (600671.SH), Renhe Pharmaceutical industry (000650. SZ), China Beads Holdings (600568. SH), Ophthalmology (300015. SZ), North China Pharmaceutical (600812). SH), the American Luo Medicine (600297. SH), Dickon Pharmaceutical industry (600466. SH), Fengyuan Pharmaceutical industry (000153.　　SZ) and other market concerns. Among them, the most drilled to a few days eye medicine. September 17, the company opened the trading, the middle of a small open trading, continued to receive trading, and finally to limit the return.　　Company insiders September 20 to the "investor" said that there is no special good recent events, the production of the main function of eye drops is eyesight and anti-fatigue, and did not treat the function of red eye disease. The outbreak is difficult to support the stock price TIANMU pharmaceutical insiders said: "The company does not use for the treatment of red eye disease of the production lot, even if the application is now to start, in the short term can not apply." "Although this, but the days of the day of the drug industry on September 17 but with the concept of red eye disease."　　A number of institutional analysts on the "investor" said that there is less concern about the outbreak of red eye disease, but some of the bio-pharmaceutical stocks are certainly related to the rise, this is because some of the hot money in the fry "super bacteria" and "tick", want to borrow red eye disease on top, to hype　　September 17, Prev fell 0.15%, in the Shanghai and Shenzhen 5 trading stocks in two of the concept of Red Eye disease Unit: China Bead Holdings and TIANMU pharmaceutical industry. On the same day, the Chinese Bead Holdings closed at 14.23 Yuan, turnover rate of 4.92%. TIANMU pharmaceutical industry closed at 14.89 Yuan, turnover rate of 19.97%.　　Ai Seoul Eye opening also once trading, the final closed at 36.15 yuan, or 5.09%.　　Although the outbreak of red eye disease in a wide range, the number of infected people more, but due to all the year round can occur, with spring and summer more than two seasons will not endanger life, not the new outbreak, caused by the panic is limited, so it is difficult to support the stock price. TIANMU pharmaceutical industry was pulled to the second trading day after the trading, and quickly to fall off the report.　　September 20, the days of the pharmaceutical industry low drive low, down to stop. According to observation, involved in the speculation of the days of the drug industry funds are fast forward fast.　　According to the open transaction information, September 17, the five big buy seats, on September 20, the choice to sell. Among them, Citic Investment securities Shenzhen Shennan Middle Road in the Nuclear Building Business Department, Everbright Securities Gold Huabing Road Sales department, CITIC Investment securities Hangzhou Jiefang Road Sales department, Citic Gold Tong securities Hangzhou Heart South Road Sales department, Oriental Securities Shanghai Pudong South Road Sales department, respectively, September 17, the first to fifth place to buy seats; second trading day, The 5 big seats are thrown out of the handsYards, respectively became the day 第一、三、二、五、四名 sold seats.　　Since the days of the September 17 basic pharmaceutical industry in the trading position, resulting in five big money groups to buy chips prices are more than 14.8 yuan; the second trading day, the average price is about 13.7 yuan, thus, some of the funds involved in speculation may have lost money. Wrong to be pulled into the concept of red eye disease in fact, if not suddenly pulled into the concept of red eye disease, TIANMU pharmaceutical industry this year compared with other stocks, more prosaic. Since the beginning of the July, the pharmaceutical sector by about 40% of the rise in the first plate, related to the concept of the leading stocks are repeatedly raised by speculation in the case of the capital, Tianmu pharmaceutical stock also failed to highlight the performance, and even the plate did not run to win, since September 17 trading, September 20, September 21 shares continued to fall,　　Return to weak trend again. Meanwhile, the listed companies that have been pulled into the concept of red eye disease also include China bead Holding and benevolence medicine.　　China bead Holding insiders said September 21 to the "investor", the company produced eye drops can be used to treat red eye disease, but because the company is now real estate, medicine two legs walk, red eye diseases outbreak, it is difficult to promote the company's performance.　　ren pharmaceutical insiders September 20 to the "investor" said that, despite the commitment of major shareholders to the eye potions business into the listed companies, but has not yet been implemented, coupled with the company's production of eye drops used to alleviate eye fatigue and prevent conjunctival inflammation, the treatment of red eye disease has no direct effect. Although Tianmu pharmaceutical, China Bead Holdings, Renhe pharmaceutical industry all said, red eye disease to pull the company's performance is less likely, in addition to the days of the pharmaceutical industry, the rest of the relevant drug companies are still likely to be brought to fry.　　Soochow Securities that the last week before the national day, investors may have a cash attitude, the market may still run in the weak pattern, the pharmaceutical biological plate short-term trend is also unspeakable optimism.　　From the perspective of long-term investment, soochow securities can be more determined to benefit from the base drug volume of the exclusive varieties of Traditional Chinese medicine, pharmaceutical business concentration to enhance the general trend of the leading pharmaceutical circulation enterprises and growth of a good, profitable growth rate, the performance of some of the security unit. It can be seen from the performance of the Tianmu pharmaceutical industry this year and the performance of major shareholders.　　This is a drug-listed company that has been abandoned by professional research institutions, and several pharmaceutical industry analysts say it has been a long time since the company was not cared for, and no research agency has written for it this year. Listed companies into the cash machine has the top ten eye drops brand "pearl eyesight Eye Drops" of the days of the pharmaceutical industry in recent years operating performance can be described as poor.　　According to the days of the pharmaceutical industry semi-annual report, the company's total revenue to achieve the main business income of 112 million yuan, compared with the previous year down 20.7%, the completion of the plan of 45.87%, only to achieve a total profit of 1.87 million yuan. Zhang Pengfei 4 years ago, the days of the pharmaceutical industry has been focused on the operation of capital, and even did not care about the company's fist production of "Pearl eyesight eye Drops" technology reform, until the first half of this year to start the project intoLine technical renovation.　　And in that period of time, Renhe group's shining Eye Drops, chia Tai Group of Clean eye drops, etc. are in rapid development. Obviously, the pharmaceutical sector profitability has always been better than most of the plate, and basically did not get hurt from the financial crisis, then the results of the TIANMU pharmaceutical industry is difficult to take.　　Interestingly, the company's performance was poor and executives were eager to raise salaries. August 18, Tianmu pharmaceutical industry announced that the review passed the "Hangzhou Tianmu Pharmaceutical Co., Ltd. Chairman and executive compensation proposals", including Chairman's remuneration to be submitted to the general Meeting of shareholders for consideration. In the voting, one of the 7 directors who attended the meeting voted against it. TIANMU Pharmaceutical Independent director Tang is: "Pay should be linked to performance, should be assessed system, the basic work must be done." "It is not difficult to see that this is a system is not a sound assessment of listed companies, the majority of shareholders are not hopeful." According to the information, the TIANMU pharmaceutical tycoon is a modern joint Investment Co., Ltd. (hereinafter referred to as Modern Union), the actual control is Zhang Pengfei and his sister Zhang Liping.　　January 2006, the modern Union from the Hangzhou Tianmu Wing group has obtained 31.26% of the Tianmu pharmaceutical industry, becoming the controlling shareholder of Tianmu pharmaceutical industry.　　However, since Zhang Pengfei took over the days of the pharmaceutical industry for more than 4 years, the company has not brought the actual positive, but there are repeated traces of capital operations, the company directly or indirectly into a Zhang Pengfei personal "atm." The modern joint takeover of the Tianmu pharmaceutical industry, has also announced plans to acquire assets to develop the main business, but nothing. December 8, 2009, the days of the pharmaceutical industry said it will buy Xin Fu Pharmaceutical factory overall assets.　　However, 20 days later, Tianmu Pharmaceutical and Xin-Fu pharmaceutical industry signed a contract to terminate the project acquisition. It is noteworthy that, on the day the two sides signed the agreement on the termination of the project, the modern union of the Tianmu pharmaceutical tycoon has reduced its share of 0.95%.　　After the reduction, Hyundai jointly holds 21.52% of the shares.　　This is not a case, according to the notice of the days of the pharmaceutical industry, Zhang Pengfei after the takeover of Tianmu Pharmaceutical, through the pledge, reduction and other means to continuously extract cash from the listed companies, in which there are frequent irregularities. Major shareholders repeatedly violated the January 13, as the days of the pharmaceutical industry in the implementation of information disclosure obligations and the internal review procedures for major issues, the continuous occurrence of the holding shareholder and its associated party is not a business to occupy the capital of the listed companies, SSE to the Tianmu pharmaceutical industry and its original chairman Zhang Pengfei, former director and general manager Zheng Zhiqiang,　　Wu Qingping, deputy finance director, denounced the public.　　By the Shanghai Stock Exchange, it was found that the shareholders and their affiliates in the days of the pharmaceutical industry in 2006-2008 years, the non-profit occupation of listed companies are 32.6 million yuan, 80.55 million yuan and 27.68 million Yuan respectively, January 2009 again occurred 3.2 million yuan.　　TIANMU pharmaceutical industry in the past one months after the Shanghai public condemnation, February 24, the company also announced that due to the large shareholder modern joint involving Zheng lawsuit case, the days of its possession of 24.88 million shares of the day of the unlimited sale of the shares were frozen, the freeze period of two years since the announcement date. 331st, Tianmu Pharmaceutical industry also announced that the West L. District People's Court in Hangzhou, Zhejiang Province, by the Zheng v. Modern United a case in February 24 was frozen the company 24.88 million unlimited sales and circulation shares (has pledged) in the 19.88 million-share lifting freeze. It is understood that Zheng originally for the TIANMU pharmaceutical Workers, formerly known as Hangzhou Tianmu Pharmaceutical Co., Ltd. Deputy general Manager (hereinafter called Tianmu Medicine), at the end of 2009 leave. Zheng's father, Zheng Zhiqiang, vice chairman and general manager of Tianmu Pharmaceutical, resigned from the above duties in November 2008 and was executive director of Tian Mu Medicine in January 2009.　　The TIANMU pharmaceutical industry on October 26, 2009 removed Zheng Zhiqiang from the executive director of TIANMU Medicine and Zheng Zhiqiang left the office at the end of 2009. Modern union has promised to give Zheng Zhiqiang 10 million Yuan reward, as of the time of the lawsuit did not cash. Zheng Zhiqiang as the former general manager of the pharmaceutical industry, has been involved in the Zhang Pengfei occupy the listed company funds events.　　January 13 this year was publicly denounced by SSE. Less than 4 months after taking back the frozen shares on March 31, Tianmu Pharmaceutical industry announced that as of July 13, the shareholders of Gold Trading Co., Ltd. (hereinafter referred to as the gold trade) cumulative sale of 1.9 million shares of the company, accounting for the total number of shares of 1.56%; after the reduction, the gold help trade still holds 7.53 million shares of the company, 6.18% of the total number of shares in the company.　　Although the company claims that the gold gang trade with the modern union of the Zhang Pengfei, however the actual controlling person of the gold trade is the younger sister Zhang Liping. Interestingly, Zhang Pengfei the 113 anniversary of the founding of Zhejiang University, he made a donation of 100 million yuan. Zhang Pengfei graduated from Zhejiang University Emba class in 2005.　　According to media reports, up to now, Zhejiang has not received Zhang Pengfei donations. In addition to the frequent violations of major shareholders, the days of the drug industry's specific drugs are also caught in the mire.　　May, in Yunnan Province Food and Drug Administration monitoring 29 illegal drug advertising in the days of the pharmaceutical subsidiary Huangshan TIANMU Pharmaceutical Co., Ltd. (hereinafter called Huangshan Tianmu) "Mulberry hemp pill."　　On April 22 this year, the Tianmu pharmaceutical industry has announced that again for the Huangshan Day to guarantee 24 million yuan, the cumulative amount of its guarantee amounted to 37 million yuan. To replace the accounting firm September 9, Tianmu Pharmaceutical announced that the review has passed the "on the Employment letter Yong and CPA firm for the 2010 annual Accounting Audit Agency of the bill."　　Yuantian Certified Public Accountants (hereinafter called Tianjian) were replaced.　　According to the reporter understanding of the insider, for Zhang Pengfei, days Health of accountants bad use, "not obedient", then replace it. There is evidence that according to the CPA Jiang Weiyue, Ye Weimin in the 2009 Annual report of the Tianmu Pharmaceutical Industry Report shows: TIANMU Pharmaceutical subsidiary Shenzhen Jing-Bai Medical Equipment Co., Ltd. (hereinafter referred to as Shenzhen Kimberg) in April 2007 to the agreement price of 15 million yuan to Boluo County Yuan Chau town, Hung star Garment factory to purchase the plant,　　and the cumulative payment of 8.783 million yuan purchase money. Since then, the TIANMU pharmaceutical industry has not obtained any proof of asset ownership and has not been directlyAccess to the asset.　　April 20, 2009, the two sides signed the supplementary agreement, the cancellation of the original purchase agreement signed, and promised to return the original prepaid in 90 days of the purchase money. Tian Jian's report shows: "As of this audit report date, Shenzhen Jing-bai Medical Equipment Co., Ltd. has not received the above purchase money." We have not been able to obtain sufficient and effective audit evidence to determine the reasonableness of the transactions and the recoverable nature of the sums. The management of TIANMU has not been able to provide sufficient and effective basis for some of the sales costs incurred in 2009 and we are unable to implement other more effective audit procedures to obtain sufficient and appropriate audit evidence to judge the occurrence of such costs and the accuracy of their presentation. "Tianmu pharmaceutical Industry in the 2010.5 Annual report to explain this, about the holding subsidiary of Shenzhen Kimberg to Boluo County Yuan Chau town hung star garment factory to buy factory, Shenzhen Kimberg received in June 29, 2010, Hung star Garment factory repayment of 500,000 yuan, August 6 received 500,000 Yuan garment factory repayment, total recovery of 1 million yuan." By the end of June 2010, there were still 7.783 million yuan.　　Tianmu Pharmaceutical decided to take legal measures to recover the balance, and is actively consulting with lawyers on how to take the next step.　　In addition, regarding the SFC April 29, 2009 to the Tianmu pharmaceutical industry to investigate the case, the company said that the SFC Zhejiang Supervision Bureau has completed investigations, the findings are also in the China Securities Regulatory Commission trial. A person who declined to be named said that it was the Zhang Pengfei's report, which had made the effort to move left to the right, and that the Half-year report had ceased cooperation with Tianjian. It is understood that has repeatedly in the SSE record Zhang Pengfei urgent need a obedient accounting firm, to ensure that the financial statements are not too ugly.　　At present, finally brother and sister in the hands of Tianmu pharmaceutical industry equity total less than 30%. However, since the gem opened since the opening, in the high growth of the industry companies have a relatively sunny listing channels, the listed company Shell Resources are no longer as valuable as before. Now demand for shell resources companies more for the bank loans Limited real estate companies, the original TIANMU pharmaceutical Total equity only 120 million shares, is still considered high-quality shell resources.